Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation TCT 2025

TCT 61: Comparative Analysis of Composite Outcomes for Double vs Triple Therapy in Patients with Atrial Fibrillation Post Percutaneous Coronary Intervention

Presenter: Khaled Elnaggar

October 28, 2025

Presentation TCT 2025

TCT 998: Dual Antiplatelet Therapy (DAT) versus Triple Therapy (TAT) post Percutaneous Coronary Intervention (PCI) in patients requiring Chronic Anticoagulation: Meta-analysis.

Presenter: Kanishk Aggarwal

October 27, 2025

Presentation TCT 2025

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

Antithrombotic Therapies in ACS: Atrial Fibrillation - Triple Therapy, Triple Threat!

Presenter: Usman Baber

October 26, 2025

News Daily News

HF Risks Stick Around Even When Ejection Fraction Improves

Todd Neale

August 01, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2025

Michael O'Riordan

June 30, 2025

Presentation NY Valves 2025

Case 4: Triple Valve Disease — Optimal Therapy Timing, Role of Surgery, and Staged Approaches

Presenter: Aakriti Gupta

June 26, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking?

Yael L. Maxwell

January 23, 2025

Advertisement

TCT 61: Comparative Analysis of Composite Outcomes for Double vs Triple Therapy in Patients with Atrial Fibrillation Post Percutaneous Coronary Intervention

TCT 998: Dual Antiplatelet Therapy (DAT) versus Triple Therapy (TAT) post Percutaneous Coronary Intervention (PCI) in patients requiring Chronic Anticoagulation: Meta-analysis.

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

Antithrombotic Therapies in ACS: Atrial Fibrillation - Triple Therapy, Triple Threat!

HF Risks Stick Around Even When Ejection Fraction Improves

TCTMD’s Top 10 Most Popular Stories for June 2025

Case 4: Triple Valve Disease — Optimal Therapy Timing, Role of Surgery, and Staged Approaches

FDA Approves Triple Therapy Polypill for High Blood Pressure

Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content